Pasar al contenido principal

DESARROLLO DE SISTEMAS BIODEGRADABLES INTRAOCULARES DE ANTIVEGF PARA EL TRATAMIENTO DE LA DEGENERACION MACULAR ASOCIADA A LA EDAD Y A RETINOPATIA DIABETICA

RTI2018-099597-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDADE DE SANTIAGO DE COMPOSTELA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Design, Optimization, and Characterization of Lactoferrin-Loaded Chitosan/TPP and Chitosan/Sulfobutylether-β-cyclodextrin Nanoparticles as a Pharmacological Alternative for Keratoconus Treatment

  • Varela Fernández, Rubén
  • García Otero, Xurxo
  • Díaz Tomé, Victoria
  • Regueiro, Uxía 
  • López López, Maite
  • González Barcia, Miguel
  • Lema Gesto, María Isabel
  • Otero Espinar, Francisco Javier
This research study describes the design, optimization, and characterization of two different types of chitosan-based nanoparticles as novel drug delivery systems of a protein drug, lactoferrin. A preclinical consistent base was obtained for both nanosystems, being considered as the first pharmacological treatment for keratoconus as an alternative to current invasive clinical methods. Both types of nanoparticles were obtained via the ionotropic gelation technique. The size and morphology of the nanoparticles were studied as a function of the preparation conditions. A mean size of 180.73 ± 40.67 nm, a size distribution [polydispersity index (PDI)] of 0.170 ± 0.067, and positive ζ-potential values, ranging from 17.13 to 19.89 mV, were achieved. Lactoferrin was successfully incorporated into both types of nanocarriers. In vitro release profiles showed a lactoferrin enhanced, prolonged, and controlled delivery from the polymeric matrix. These formulations also demonstrated no stability or cytotoxicity problems, as well as appropriate mucoadhesive properties, with a high permanence time in the ocular surface. Thus, both types of nanoparticles may be considered as nanocarriers for the controlled release of lactoferrin as novel topical ophthalmic drug delivery systems.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Development And Characterization Of A Tacrolimus/hydroxypropyl-β-cyclodextrin Eye Drop

  • Bermúdez, María José
  • Varela-Fernández, Rubén
  • García-Otero, Xurxo
  • Díaz Tomé, Victoria
  • Martín-Pastor, Manuel
  • González-Barcia, Miguel
  • Blanco Méndez, José
  • Mondelo-García, Cristina
  • González, Francisco
  • Aguiar, Pablo
  • Fernández Ferreiro, Anxo
  • Otero Espinar, Francisco Javier
[Abstract] Uveitis is a vision inflammatory disorder with a high prevalence in developing countries. Currently, marketed treatments remain limited and reformulation is usually performed to obtain a tacrolimus eye drop as a therapeutic alternative in corticosteroid-refractory eye disease. The aim of this work was to develop a mucoadhesive, non-toxic and stable topical ophthalmic formulation that can be safely prepared in hospital pharmacy departments. Four different ophthalmic formulations were prepared based on the tacrolimus/hydroxypropyl-β-cyclodextrin (HPβCD) inclusion complexes’ formation. Phase solubility diagrams, Nuclear Magnetic Resonance (NMR) and molecular modeling studies showed the formation of 1:1 and 1:2 tacrolimus/HPβCD inclusion complexes, being possible to obtain a 0.02% (w/v) tacrolimus concentration by using 40% (w/v) HPβCD aqueous solutions. Formulations also showed good ophthalmic properties in terms of pH, osmolality and safety. Stability studies proved these formulations to be stable for at least 3 months in refrigeration. Ex vivo bioadhesion and in vivo ocular permanence showed good mucoadhesive properties with higher ocular permanence compared to the reference pharmacy compounding used in clinical settings (t1/2 of 86.2 min for the eyedrop elaborated with 40% (w/v) HPβCD and Liquifilm® versus 46.3 min for the reference formulation). Thus, these novel eye drops present high potential as a safe alternative for uveitis treatment, as well as a versatile composition to include new drugs intended for topical ophthalmic administration., This research was partially supported by the Spanish Ministry of Science, Innovation and Universities (RTI2018-099597-B-100), the ISCIII (PI17/00940, RETICS Oftared, RD16/0008/0003 and RD12/0034/0017) and by Xunta de Galicia, grant numbers GPC2013/015 and GRC2017/015. X.G.-O. and R.V.-F. acknowledge the financial support of the IDIS (Health Research Institute of Santiago de Compostela) (predoctoral research fellowships). P.A. acknowledges the support of RYC-2015/17430 (Ramón y Cajal). A.F.-F. acknowledges the support received from the Instituto de Salud Carlos III (ISCIII) through its Juan Rodes grant (JR18/00014)., Xunta de Galicia; GPC2013/015, Xunta de Galicia; GRC2017/015